Beverly Hills, California — August 7, 2025 — Leads & Copy — Nordicus Partners Corporation (OTCQB: NORD) has announced changes to its Board of Directors. Henrik Keller resigned to pursue other interests, and the Board has been expanded from three to five members. Torben Jensen, Kim T. Mücke, and Andrew J. Ritter have been appointed to fill the vacancies.
Henrik Rouf, CEO of Nordicus, thanked Keller and welcomed the new members. Jensen, a major shareholder, will assist in funding Nordicus and its subsidiaries. Mücke, with experience in accounting, will chair the Audit Committee. Ritter, an experienced CEO in the pharma space, will assist in corporate finance and strategic relationships.
Jensen has over 35 years of experience in finance and has funded projects in real estate, energy, venture, life science, and medico. Mücke is a Danish state-authorized public accountant and was a partner with Deloitte (Denmark) and Head of Corporate Clients for BDO (Denmark). Ritter has served as CEO of Cairns Health, Docbot, and Ritter Pharmaceuticals.
Nordicus Partners Corporation is a business accelerator and holding company for Nordic life sciences companies. In 2024, it acquired Orocidin A/S and Bio-Convert A/S.
Contact:
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email hr@nordicuspartners.com
Source: Nordicus Partners Corporation
